WATERTOWN, Mass.--(BUSINESS WIRE)--April 28, 2005--
New market intelligence module allows marketers to assess the market performance of drugs that are commonly prescribed as combination therapies with an unparalleled level of accuracy
PharMetrics (www.pharmetrics.com) announced today the immediate availability of its new Combination Therapy market intelligence module. The module, which is a new addition to the company's Brand Profiler product, allows marketers to assess the market performance of drugs that are often prescribed as combination therapies for the treatment of a specific disease with a previously unparalleled level of accuracy.
